Angiogenesis

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of 

Articles

Presenters at the conference provided new evidence about detecting geography atrophy and wet and dry AMD early and predicting disease progression. Investigators are also focused on finding cures for inherited retinal diseases.

Highlighting major advances in retinal diagnostics, therapeutics presented at Angiogenesis 2022

Videos

At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.

CANDELA Phase 2 results indicate benefits in high dose aflibercept for wet AMD

Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wet AMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.

UBX1325 Phase 1 study data revealed at Angiogenesis

A brief overview of findings presented at the 2022 Angiogenesis, Exudation and Degeneration meeting hosted by Bascom Palmer.

Angiogenesis 2022: Study results reveal novel options for geographic atrophy, diabetic eye disease

Investigators in the Netherlands have developed an RNA therapy to halt the progression of Stargardt disease.

RNA therapy may halt the progression of Stargardt disease

Dr. Carel Hoyng divulges the main takeaways from his Angiogenesis presentation, including the origins of Stargardt disease, correct diagnosis, ongoing gene therapy trials and the future of therapy.

Stargardt research explores RNA, gene therapy options

Dr. Carl Regillo discusses the 100-week results of KESTREL and KITE, two pivotal Phase 3 studies for brolucizumab for the treatment of diabetic macular edema.

100-week results of KESTREL, KITE push brolucizumab toward FDA approval

Dr. Arshad M. Khanani reviews the Phase 2 part A results of the KALAHARI study of THR-149 for the treatment of DME.

High dose of THR-149 delivers BCVA increase, stable CST in KALAHARI study

KALAHARI study finds THR-149 to be safe, well-tolerated with preliminary efficacy as treatment for DME patients who respond suboptimally to anti-VEGF.

KALAHARI study finds THR-149 to be safe, well-tolerated as treatment for DME

Most patients (95%) with the PDS implanted did not need supplemental treatment before the refills, indicating the persistence and durability of the treatment.